News
Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc
Form 8.3 - The Vanguard Group, Inc.: Petershill Partners plc
Form 8.3 - The Vanguard Group, Inc.: Bakkavor Group plc
Form 8.3 - The Vanguard Group, Inc.: Just Group plc
Form 8.3 - The Vanguard Group, Inc.: NCC Group plc
Form 8.3 - The Vanguard Group, Inc.: Unite Group plc, The
Form 8.3 - The Vanguard Group, Inc.: Spectris plc
Form 8.3 - The Vanguard Group, Inc.: Big Yellow Group plc
Hardman & Co research on Real Estate Credit Investments (RECI): Investor Day: opportunities aplenty
Carronade’s Nominees Present Significant Risks to Cannae Shareholders
Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) today issued the following statement regarding Cannae’s strategic transformation and the election of directors to Cannae’s Board of
EQS-News: DoctorBox Adds Mainz Biomed’s ColoAlert® to Its Portfolio
Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
MULTI UNITS FRANCE: NOTICE TO SHAREHOLDERS
Amundi Asset Management: NOTICE TO SHAREHOLDERS
EQS-News: Elmos Semiconductor SE at CES in Las Vegas: Intelligent semiconductor solutions for the mobility of the future
EQS-News: Correction of a release from 01/12/2025, 14:26 CET/CEST - Turnover and order backlog development at the end of the 2025/2026 fiscal half-year (November 30, 2025)
EQS-News: LION E-Mobility AG: Daniel Stitz and Alex Triglia strengthen European BESS Sales
EQS-News: ParTec AG: Major milestone for the QSolid project – integration and first external user access strengthen German quantum computing ecosystem
Gold Reserve Provides Update in CITGO Sale Process: Multiple Parties Appeal Final Sale Order
Gold Reserve Ltd. (TSX.V: GRZ) (BSX: GRZ.BH) (OTCQX: GDRZF) (“Gold Reserve” or the “Company”) announces that today it filed a notice of appeal to the U.S. Court of Appeals for the Third Circuit
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast




